Institutional Review Board IRB Informed Consent Document Template

INSTITUTIONAL REVIEW BOARD (IRB) INFORMED CONSENT DOCUMENT

DOCUMENT CONTROL & METADATA

• Effective Date: [Effective Date]
• Document Version: [Version Number, e.g., 2.1]
• Protocol ID / IRB Tracking Number: [IRB Protocol #]
• Jurisdiction / Regulatory Scope: United States (45 CFR 46, 21 CFR 50, 21 CFR 56) & Applicable International Standards (ICH GCP E6)

---

1. OFFICIAL NOTICE & COMPLIANCE DISCLAIMER

LEGAL NOTICE: This document is a template designed to comply with United States Department of Health and Human Services (HHS) regulations for the protection of human subjects. Customization is required to reflect specific institutional policies, protocol methodologies, and risk profiles. Legal and regulatory counsel should review the final protocol-specific adaptation prior to Institutional Review Board (IRB) submission and subject recruitment.

---

2. PARTIES & DEFINITIONS

• Principal Investigator (PI): [Principal Investigator Full Name, MD/PhD], representing [Institution / Research Facility Name] ("Institution").
• Sponsor / Funding Body: [Sponsor Corporation or Agency Name], including its agents, contractors, and assigns ("Sponsor").
• Research Subject ("Subject"): [Full Legal Name of Participant], acting individually or via a legally authorized representative ([Name of Legal Representative, if applicable]).

Key Definitions:

• "Clinical Investigation / Research Study" means the systematic investigation designed to develop or contribute to generalizable knowledge, specifically titled: [Full Protocol Title].
• "Protected Health Information (PHI)" means individually identifiable health information transmitted or maintained in any form or media, whether electronic, paper, or oral, collected pursuant to this study.

---

3. OPERATIVE CLAUSES & TERMS

1. Purpose and Voluntary Participation

You are being asked to take part in a research study. Participation is entirely voluntary. You may refuse to participate, or you may withdraw your consent and discontinue participation at any time without penalty, loss of benefits to which you are otherwise entitled, or compromise of your standard medical care at [Institution Name].

2. Study Procedures and Duration

If you agree to participate, you will be asked to undergo the following procedures:

• [Detailed, step-by-step description of intervention, randomization, blinding, and data/sample collection protocols].
• Duration: Your active participation in this study will last approximately [Number of Days/Months/Years], involving [Number] of study visits, each lasting approximately [Number] hours.

3. Risks, Discomforts, and Inconveniences

Participation in this study may involve foreseeable risks, discomforts, or adverse effects, including:

• Physical Risks: [Specific physical side effects, procedural risks, e.g., minor bruising, localized infection, adverse drug reactions].
• Psychological/Social Risks: [Potential emotional distress, breach of confidentiality risks].
• Unforeseen Risks: The interventions or treatments may involve risks that are currently unforeseeable. You will be informed in a timely manner of any significant new findings that may affect your willingness to continue participating.

4. Potential Benefits

• Direct Benefits: You may or may not receive direct medical benefit from participating in this study. Potential benefits include [Describe direct benefits, e.g., closer monitoring of condition].
• General Benefits: Information gathered from this study may contribute to scientific and medical knowledge regarding [Target Disease/Condition/Technology].

5. Compensation and Costs

• Compensation: You will receive [$ Amount] per completed study visit, up to a total of [$ Maximum Total Amount], for your time, travel, and related inconveniences. If you withdraw early, you will be compensated pro rata for completed milestones.
• Costs: There will be no additional cost to you for the diagnostic tests, drugs, or procedures directly required by the research protocol. Standard medical care remains your (or your insurer's) financial responsibility.

6. Confidentiality and Data Protection

Your identity and records generated by this study will be kept confidential in accordance with applicable federal and state laws.

• Access to Records: Representatives of the [Institution Name] IRB, the Sponsor ([Sponsor Name]), and regulatory authorities (such as the U.S. Food and Drug Administration) may inspect your research and medical records to verify study integrity.
• Data Publication: Results of this study may be published in scientific literature or presented at medical meetings, but your identity will not be disclosed without explicit authorization.

7. Injury Compensation

In the event of physical injury resulting directly from research procedures, emergency medical treatment will be provided by [Institution Name]. Financial compensation or coverage for lost wages/long-term care [is / is not] provided by [Sponsor Name] beyond immediate emergency medical care. Signing this form does not waive your legal rights.

8. Contacts and Questions

• For questions about the study, potential injuries, or adverse events, contact the Principal Investigator, [Principal Investigator Name], at [Phone Number] or [Email Address].
• For questions regarding your rights as a research subject, complaints, or independent concerns, contact the Institutional Review Board Office at [IRB Phone Number] or [IRB Email Address].

---

4. SIGNATURES & ACKNOWLEDGMENT BLOCK

SUBJECT / LEGALLY AUTHORIZED REPRESENTATIVE STATEMENT

I confirm that I have read this informed consent document (or it has been read to me). The study protocol, its risks, benefits, and alternatives have been explained to me in detail. I have had the opportunity to ask questions, and all questions have been answered to my satisfaction. I voluntarily agree to participate in this research study and authorize the collection, use, and disclosure of my Protected Health Information as described herein.

---

Printed Name of Research Subject

---

Signature of Research Subject Date (MM/DD/YYYY)

(Complete only if Subject is a minor or lacks capacity to consent)

---

Printed Name of Legally Authorized Representative (LAR)

---

Signature of LAR Date (MM/DD/YYYY) Relationship to Subject: [e.g., Parent, Legal Guardian, Power of Attorney]

PERSON OBTAINING CONSENT STATEMENT

I certify that I have accurately explained the nature and purpose of this clinical investigation to the subject and/or their legal representative, and outlined the potential risks and benefits. To the best of my knowledge, the individual signing this document understands the nature, demands, risks, and benefits of participation and has freely given informed consent.

---

Printed Name of Person Obtaining Consent

---

Signature of Person Obtaining Consent Date (MM/DD/YYYY)

---

5. STEP-BY-STEP EXECUTION GUIDE

1. Protocol Customization: Replace all bracketed text (e.g., [Company Name], [Principal Investigator Name]) with precise protocol parameters approved by the local Institutional Review Board prior to subject recruitment.
2. Pre-Consent Discussion: The Principal Investigator or a designated, qualified sub-investigator must conduct an exhaustive verbal review of this document with the prospective subject in a private, confidential setting.
3. Execution & Dual Signing: Ensure both the subject (or Legally Authorized Representative) and the designated study personnel obtain signatures and dates concurrently at the time consent is granted. Backdating is strictly prohibited.
4. Distribution & Archival: Provide a fully executed copy of this consent form to the subject immediately. Retain the original master document in the Investigator Site File (ISF) and upload a digital copy to the secure clinical trial management system (CTMS) or electronic health record (EHR) as mandated by institutional policy.